The prognostic value of the post-treatment serum CA 125 level in patients with advanced endometrial cancer
, 1, 1, 1, 1, 1, 1, 1
Abstract
Objectives: The goal of this analysis was to assess the prognostic value of the post-treatment serum CA 125 level in each member of a group of advanced endometrial cancer (aEC) patients in comparison to other clinical and pathological parameters.
Material and methods: Records of 266 patients treated at the Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Cracow Branch between the years 2006 and 2018 were included in the study. Follow-up ranged from 1 to 138 months. Progression free survival (PFS) and overall survival (OS) were set as the endpoints. The tests chi-squared, Fisher, log-rank, Mann-Whitney, Kruskal-Wallis and Cox proportional hazard ratio were used for statistical analyses.
Results: In the analysed group, there was a significant association between an elevated serum CA 125 level following adjuvant treatment and shorter PFS and OS. After setting a cut-off value for CA 125 there was a statistically significant correlation between the marker and PFS and OS. Multivariate analysis indicated that the post-treatment serum CA 125 level is an independent prognostic factor of the course of aEC.
Conclusions: The post-treatment serum CA 125 level correlates significantly with both PFS and OS in each patient with aEC. The marker is an independent prognostic factor in this group. A low post-treatment level of the marker is a strong indicator of good 5-year survival, with 82% of patients reaching 5-year OS.
Keywords: advanced endometrial cancerCA 125post-treatmentadjuvant treatment
References
- Didkowska J, Wojciechowska U, Olasek P, dos Santos FC, Michałek I. Nowotwory złośliwe w Polsce w 2019 roku. Narodowy Instytut Onkologii Państwowy Instytut Badawczy, Warszawa 2021.
- GLOBOCAN 2018, Cancer Incidence Mortality and Prevalence Worldwide 2018. http://gco.iarc.fr/today (11.06.2023).
- KRN – Krajowy Rejestr Nowotworów. http://onkologia.org.pl (11.06.2023).
- Duk JM, Aalders JG, Fleuren GJ, et al. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol. 1986; 155(5): 1097–1102.
- Patsner B, Mann WJ, Cohen H, et al. Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol. 1988; 158(2): 399–402.
- Sood AK, Buller RE, Burger RA, et al. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997; 90(3): 441–447.
- Hsieh CH, ChangChien CC, Lin H, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol. 2002; 86(1): 28–33.
- Hsieh CH, ChangChien CC, Lin H, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol. 2002; 86(1): 28–33.
- Zhou X, Wang H, Wang X. Preoperative CA125 and fibrinogen in patients with endometrial cancer: a risk model for predicting lymphovascular space invasion. J Gynecol Oncol. 2017; 28(2): e11.
- Shawn LyBarger K, Miller HA, Frieboes HB. CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting. Sci Rep. 2022; 12(1): 19783.
- Knific T, Osredkar J, Smrkolj Š, et al. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer. Gynecol Oncol. 2017; 147(1): 126–132.
- Yang B, Shan B, Xue X, et al. Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models. PLoS One. 2016; 11(5): e0155145.
- Patsner B, Tenhoppen DJ, Mann WJ. Use of serum CA-125 levels to monitor therapy of patients with advanced or recurrent endometrial carcinoma. Eur J Gynaecol Oncol. 1989; 10(5): 322–325.
- Hoskins PJ, Le N, Correa R. CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer. Gynecol Oncol. 2011; 120(1): 52–55.
- Davelaar E, Kamp Gv, Verstraeten R, et al. Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clinical Chemistry. 1998; 44(7): 1417–1422.
- Muzykiewicz KP, Iwanska E, Janeczek M, et al. The analysis of the prognostic value of the neutrophil/ lymphocyte ratio and the platelet/lymphocyte ratio among advanced endometrial cancer patients. Ginekol Pol. 2021; 92(1): 16–23.
- Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2016; 26(1): 2–30.
- Patsner B, Yim GaW. Predictive value of preoperative serum CA-125 levels in patients with uterine cancer: The Asian experience 2000 to 2012. Obstet Gynecol Sci. 2013; 56(5): 281–288.
- Pennington K, Reynolds R. Usefulness of serial CA-125 levels in surveillance of endometrial cancer. Gynecologic Oncology. 2011; 120: S97.
